These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 30588095)
1. Clinicopathological significance of DAPK promoter methylation in non-small-cell lung cancer: a systematic review and meta-analysis. Zhang Y; Wu J; Huang G; Xu S Cancer Manag Res; 2018; 10():6897-6904. PubMed ID: 30588095 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis. Chen Z; Fan Y; Liu X; Shang X; Qi K; Zhang S Int J Biol Markers; 2022 Mar; 37(1):47-57. PubMed ID: 34935548 [TBL] [Abstract][Full Text] [Related]
3. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study. Yang XY; Zhang J; Yu XL; Zheng GF; Zhao F; Jia XJ J Cancer Res Ther; 2018; 14(Supplement):S65-S71. PubMed ID: 29578152 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis. Li Y; Zhu M; Zhang X; Cheng D; Ma X Drug Des Devel Ther; 2015; 9():1785-96. PubMed ID: 25848215 [TBL] [Abstract][Full Text] [Related]
5. DAPK promoter methylation status correlates with tumor metastasis and poor prognosis in patients with non-small cell lung cancer. Zhang J; Yu XL; Zheng GF; Zhao F Cancer Biomark; 2015; 15(5):609-17. PubMed ID: 26406950 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review. Song X; Shi K; Zhou SJ; Yu DP; Liu Z; Han Y Drug Des Devel Ther; 2016; 10():1345-54. PubMed ID: 27103788 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis. Xu L; Lan H; Su Y; Li J; Wan J Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616 [TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of RARβ2, DAPK, hMLH1, p14, and p15 is associated with progression of breast cancer: A PRISMA-compliant meta-analysis. Qi M; Xiong X Medicine (Baltimore); 2018 Dec; 97(51):e13666. PubMed ID: 30572486 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of WIF1 hypermethylation in NSCLC, a meta-analysis and literature review. Guo H; Zhou S; Tan L; Wu X; Wu Z; Ran R Oncotarget; 2017 Jan; 8(2):2550-2557. PubMed ID: 27911280 [TBL] [Abstract][Full Text] [Related]
11. Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis. Li FF; Yang Y; Wang XL; Hong YY; Wang NF; Chen ZD Tumour Biol; 2014 Jun; 35(6):6011-20. PubMed ID: 24659425 [TBL] [Abstract][Full Text] [Related]
12. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer. Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112 [TBL] [Abstract][Full Text] [Related]
13. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma. Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394 [TBL] [Abstract][Full Text] [Related]
14. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445 [TBL] [Abstract][Full Text] [Related]
15. DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis. Dai L; Ma C; Zhang Z; Zeng S; Liu A; Tang S; Ren Q; Sun Y; Xu C PLoS One; 2016; 11(12):e0167228. PubMed ID: 27907054 [TBL] [Abstract][Full Text] [Related]
16. DAPK promoter hypermethylation in tissues and body fluids of oral precancer patients. Liu Y; Zhou ZT; He QB; Jiang WW Med Oncol; 2012 Jun; 29(2):729-33. PubMed ID: 21516484 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance and potential drug target of T-cadherin in NSCLC. Wang Z; Wang B; Guo H; Shi G; Hong X Drug Des Devel Ther; 2015; 9():207-16. PubMed ID: 25565774 [TBL] [Abstract][Full Text] [Related]
18. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876 [TBL] [Abstract][Full Text] [Related]
19. Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Kuester D; Dar AA; Moskaluk CC; Krueger S; Meyer F; Hartig R; Stolte M; Malfertheiner P; Lippert H; Roessner A; El-Rifai W; Schneider-Stock R Neoplasia; 2007 Mar; 9(3):236-45. PubMed ID: 17401463 [TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation patterns of P16, DAPK and MGMT in oral squamous cell carcinoma: a systematic review and meta-analysis. Don KR; Ramani P; Ramshankar V; Sherlin HJ; Premkumar P; Natesan A Indian J Dent Res; 2014; 25(6):797-805. PubMed ID: 25728117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]